# X4 Pharmaceuticals Inc. (XFOR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.04, market value $401 million.

## Valuation
- **P/E (trailing): 2.8×**. X4 Pharmaceuticals Inc. trades at 2.8× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 42.4×**. Each dollar of revenue is priced at 42.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 35.4%**. The inverse of the P/E: 35.4% of the price is earned each year.

## Profitability
- **Operating margin: -931.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -225.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -42.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -157.0%**. Return on all capital, debt included, is -157.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -31.0%**. Each dollar of assets produces -31.0% of profit.

## Growth
- **Revenue growth (1 yr): 1273.2%** (5-yr 63.6%/yr). Revenue grew 1273.2% over the last year, against 63.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 66.5%**. Earnings per share rose 66.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.40**. Debt is 0.40 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.6×**. It would take 1.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.34**. A Z-score of 2.34 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. X4 Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 11.0%** (YTD 1.0%, 3-mo 5.5%). The shares are up 11.0% over twelve months including dividends.
- **From 52-week high: -16.4%** (44.3% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 2.36** (volatility 75%). Beta of 2.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=XFOR · Page: https://foliofundamentals.com/stocks/xfor

Not investment advice.